anti- Villin antibodyСпецификация| Clonality | monoclonal | | Host | Mouse | | Specificity | Human, Mouse | | Tested Application | ELISA, WB, IHC, IF, IP | | Delivery Time | 2 to 4 working days | | Clone ID | 3D11 | | Isotype | IgG1 | | Form | liquid | | Purification | Protein A+G purification | | Purity | ≥95% as determined by SDS-PAGE | | Uniprot ID | P09327 | | Calculated MW | 93 kDa | | Ссылка на страницу на сайте производителя | ссылка | | Инструкция | PDF | | Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.) | | Background | Villin 1(VIL1) is a 95-kd F-actin bundling and severing protein and its expression is restricted to epithelial cells with a brush border, like epithelial cells of the intestinal mucosa, gall bladder, renal proximal tubules and ductuli efferentes of the testis. VIL1 has been reported to be an epithelial cell-specific anti-apoptotic protein, and to have an important function in regulating actin dynamics, cell morphology, epithelial-to-mesenchymal transitions, cell migration and cell survival. In addition, VIL1 is a useful diagnostic marker for of various cancer, like cervical and endometrial adenocarcinomas, renal cell carcinoma. VIL1 was recently identified as a novel biomarker predictive for postoperative recurrence and poorer prognosis of high serum AFP associated HCC. | | Immunogen | villin 1 | | Synonyms | VIL, VIL1, Villin, villin 1 | | Recommended dilution | WB: 1:500-1:5000; IHC: 1:50-1:2000; IF: 1:10-1:100; IP: 1:500-1:5000 | Immunohistochemistry of paraffin-embedded human colon cancer tissue slide using FNab09407(VIL1 Antibody) at dilution of 1:50?
 | human kidney tissue were subjected to SDS PAGE followed by western blot with FNab09407(VIL1 antibody) at dilution of 1:1000
 | | | |
Информация для заказа| Область использования: | Производство: | Fine Biotech | | Метод: | Антитела | | Объем: | 100µg | | Кат. номер: | FNab09407 | | Цена (с НДС 20%): | по запросу | В корзину  | Наименование: anti- Villin antibody. Примечание: |
|